Navigation Links
Kosan Presents Preclinical Data on Novel Third-Generation Hsp90 Inhibitors at AACR
Date:4/16/2008

HAYWARD, Calif., April 16 /PRNewswire-FirstCall/ -- Kosan Biosciences Incorporated (Nasdaq: KOSN) presented data on its novel, proprietary third-generation Hsp90 inhibitors demonstrating a high degree of target specificity, strong binding affinity and potency, a long lifetime in tumor tissue and significant antitumor activity and safety in murine xenograft and orthotopic models.

Hsp90 is a protein chaperone that acts to stabilize and/or activate a number of proteins required for cellular signaling pathways, including several known determinants of carcinogenesis such as HER2 (Erb2), B-Raf, c-Kit, Flt-3 and Raf-1. Hsp90 is effectively inhibited by benzoquinone ansamycins, such as geldanacmycin and its derivatives, which bind to the ATP binding site in the N-terminal domain. Kosan's lead Hsp90 inhibitor, tanespimycin (17-AAG), is a geldanamycin derivative. Kosan's third-generation Hsp90 inhibitors are non-benzoquinone ansamycins that have been genetically engineered to retain a high degree of specificity of tanespimycin for the ATP binding pocket of Hsp90 yet do not rely upon activation of the quinone moiety for maximal inhibitor activity. These third-generation Hsp90 inhibitors are highly potent molecules in tumor models with properties that significantly distinguish them from other Hsp90 inhibitors.

"Kosan's third-generation Hsp90 inhibitors expand our Hsp90 portfolio, and represent opportunities for product diversification and life-cycle extension," said Helen S. Kim, Kosan's President and Chief Executive Officer. "Developing tanespimycin, our first generation Hsp90 inhibitor, in multiple myeloma and in breast cancer, is Kosan's highest priority. We believe that our next-generation molecules add value to our Hsp90 program an
'/>"/>

SOURCE Kosan Biosciences Incorporated
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Kosan Restructures Workforce to Focus Resources on Lead Clinical Programs
2. Kosans Board of Directors Appoints Helen S. Kim as Chief Executive Officer
3. Kosan Biosciences to Present at the Cowen and Company 28th Annual Health Care Conference
4. Kosan Biosciences to Present at the Susquehanna Second Annual SIGnificant Options in Healthcare Conference
5. Kosan Announces Senior Management Changes and Clinical Portfolio Priorities
6. Kosan Announces Fourth Quarter and Full Year 2007 Financial Results and 2008 Outlook
7. Kosan Announces February 28, 2008 Conference Call and Webcast
8. Kosans Hsp90 Inhibitor, Tanespimycin, Shows 55% Clinical Benefit in Patients With Trastuzumab-Refractory Metastatic Breast Cancer
9. Kosan Announces Third Quarter 2007 Financial Results
10. Kosan to Reacquire Epothilone Program From Roche
11. Kosan Biosciences to Host Research & Development Day on October 31, 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... Chips that use light, rather than electricity, to ... and energy efficiency is a growing concern as ... chief components of optical circuits light emitters, ... to build. One promising light source for optical ... optical properties when deposited as a single, atom-thick ...
(Date:9/19/2014)... -- Pfenex Inc. (NYSE MKT: PFNX), a clinical-stage biotechnology ... to manufacture proteins including biosimilar therapeutics, today announced that ... Annual NewsMakers in the Biotech Industry conference in ... chief executive officer of Pfenex, will provide an overview ... Friday, September 26, 2014 at 10:00 a.m. EDT/7:00 a.m. ...
(Date:9/19/2014)... September 19, 2014 , The ... Society for Paediatric Endocrinology (ESPE) Meeting  Investment ... medical research in the field of growth  , ... Germany , today announced the first ... 2014. The awards were announced during a Satellite Symposium ...
(Date:9/18/2014)... , Sept. 18, 2014 /PRNewswire-iReach/ -- DeepResearchReports.com ... China Acetic Acid Industry" and "2014 Deep Research ... reports to its research database. Photo ... Deep Research Report on Global and China Acetic ... report on China and ...
Breaking Biology Technology:Toward optical chips 2Toward optical chips 3Pfenex to Present at Upcoming Industry Conference on September 26 2EMD Serono Awards Grant for Growth Innovation (GGI) for the First Time 2EMD Serono Awards Grant for Growth Innovation (GGI) for the First Time 3Acetic Acid Market & Sodium Stannate Industry (China, Global) Research Report 2Acetic Acid Market & Sodium Stannate Industry (China, Global) Research Report 3Acetic Acid Market & Sodium Stannate Industry (China, Global) Research Report 4
... (NYSE AMEX: IBIO ) today announced that it has ... Annual Stockholders Meeting to be held December 8, 2011 at iBio,s ... AM ET. Although only stockholders of record as ... entitled to vote at the meeting, anyone with proof of ownership ...
... materials science and engineering (MSE) researchers have demonstrated ... how energy levels align in a critical group ... breakthrough in the development of sustainable technologies such ... (OLEDs). Transition metal oxides, which are best-known ...
... Nov. 5, 2011 Jennerex, Inc., a private clinical-stage ... of first-in-class targeted oncolytic products for cancer, today presented ... trial of JX-594 in patients with advanced liver cancer ... the high JX-594 dose group versus the low dose ...
Cached Biology Technology:iBio Sets Record Date and Location for December 8 Annual Meeting of Stockholders 2Jennerex Presents Final Data From JX-594 Randomized Phase 2 Clinical Trial Showing Statistically Significant Survival Benefit in Patients With Advanced Liver Cancer 2Jennerex Presents Final Data From JX-594 Randomized Phase 2 Clinical Trial Showing Statistically Significant Survival Benefit in Patients With Advanced Liver Cancer 3Jennerex Presents Final Data From JX-594 Randomized Phase 2 Clinical Trial Showing Statistically Significant Survival Benefit in Patients With Advanced Liver Cancer 4Jennerex Presents Final Data From JX-594 Randomized Phase 2 Clinical Trial Showing Statistically Significant Survival Benefit in Patients With Advanced Liver Cancer 5Jennerex Presents Final Data From JX-594 Randomized Phase 2 Clinical Trial Showing Statistically Significant Survival Benefit in Patients With Advanced Liver Cancer 6
(Date:9/18/2014)... stored in DNA, tiny strands of nucleic acid that ... express this genetic data, our DNA is copied into ... that perform tasks in our cells. , Several ... molecule. Unlike all other known RNAs, this molecule is ... are abundant, little has been known about how they ...
(Date:9/18/2014)... Arizona turned its newborn screening program into a model other ... it the first-ever Newborn Screening Quality Award from the March ... Humble, M.P.H., Arizona,s Department of Health Services director, with the ... a policy of full transparency for the length of time ... the lab for analysis, and set a target of having ...
(Date:9/18/2014)... happy-go-lucky characters, so you might expect that most would ... fact some dogs are distinctly more pessimistic than others, ... "This research is exciting because it measures positive and ... offers researchers and dog owners an insight into the ... Melissa Starling, from the Faculty of Veterinary Science. Her ...
Breaking Biology News(10 mins):Scientists find how mysterious 'circular RNA' is formed, claim muscular dystrophy link 2March of Dimes honors Arizona with first-ever newborn screening award 2March of Dimes honors Arizona with first-ever newborn screening award 3Dogs can be pessimists too 2Dogs can be pessimists too 3
... Health, science and medical reporters are invited to register ... Scientific Meeting March 24 at Moscone Center (North), San ... to focus on the results of care-changing investigations that ... options, advance patient care and improve quality of life. ...
... Seeking to maximise the value of computational modelling ... Registration, Evaluation, Authorisation and Restriction of Chemicals (REACH), ... (PETA) Foundation has produced a free resource for ... on the use of Quantitative Structure Activity Relationships ...
... 2007, a controversial pesticide was approved by the Food and ... in California and Florida. Farm workers and scientists protested the ... is a known carcinogen. Now, MU researchers are studying the ... could be made more efficient and safer for those living ...
Cached Biology News:Media alert: Press registration open for 2012 SIR Annual Scientific Meeting 2PETA launches in silico testing resource to reduce number of animal tests 2MU scientists study how to improve pesticide efficiency 2
... Cell permeable fluorescent minor groove-binding probe ... of double-stranded DNA (preferentially to AT rich ... approximately 20 times greater than DAPI alone. ... ethidium bromide for staining DNA in agarose ...
... The 96 PW is an intelligent full ... washing all wells simultaneously. This instrument gives you ... and outstanding washing efficiency , Performance ... throughput and excellent wash efficiency. A dispense precision ...
... CE 4100 high pressure dual piston pump and ... for added flexibility. The system is ... unit, CE 4901., The CE 4901 PowerStream software ... with Windows 98 and 2000, offers the same ...
...
Biology Products: